stockportfolio.pro
Stocks / VKTX vs WRBY
VKTX vs WRBY
Viking Therapeutics, Inc. and Warby Parker Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Viking Therapeutics, Inc. (VKTX) | Warby Parker Inc. (WRBY) | |
|---|---|---|
| Market cap | $3.2B | $3.2B |
| Revenue (latest FY) | $0 | $871.90M |
| Net income (latest FY) | $-359.64M | $1.64M |
| Revenue growth (5y CAGR) | — | 17.2% |
| Net margin | — | 0.2% |
| Return on equity | -56.3% | 0.4% |
| P/E ratio | — | 2581.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | — | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open VKTX — free Open WRBY — freeFrequently asked questions
Which is bigger, VKTX or WRBY?
Viking Therapeutics, Inc. is larger by market capitalization — $3.2B versus $3.2B.
Which grows faster, VKTX or WRBY?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.